These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 24047067)

  • 1. Tracking drugs.
    Huang J
    N Engl J Med; 2013 Sep; 369(12):1168-9. PubMed ID: 24047067
    [No Abstract]   [Full Text] [Related]  

  • 2. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay.
    Martinez Molina D; Jafari R; Ignatushchenko M; Seki T; Larsson EA; Dan C; Sreekumar L; Cao Y; Nordlund P
    Science; 2013 Jul; 341(6141):84-7. PubMed ID: 23828940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug dosing in older patients with chronic kidney disease.
    Perrin E
    Am Fam Physician; 2007 Dec; 76(12):1766. PubMed ID: 18217516
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapeutic drug monitoring--the appropriate use of drug level measurement in the care of the neonate.
    Young TE
    Clin Perinatol; 2012 Mar; 39(1):25-31. PubMed ID: 22341534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacologic monitoring in elderly persons].
    Royer RJ; Pierfitte C; Hanesse B
    Bull Soc Sci Med Grand Duche Luxemb; 1996; 133(2):35-8. PubMed ID: 9064221
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacokinetic changes in critical illness.
    Boucher BA; Wood GC; Swanson JM
    Crit Care Clin; 2006 Apr; 22(2):255-71, vi. PubMed ID: 16677999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug dosing adjustments in patients with chronic kidney disease.
    Munar MY; Singh H
    Am Fam Physician; 2007 May; 75(10):1487-96. PubMed ID: 17555141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring drug-protein interaction.
    Yang XX; Hu ZP; Chan SY; Zhou SF
    Clin Chim Acta; 2006 Mar; 365(1-2):9-29. PubMed ID: 16199025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safe and effective variability-a criterion for dose individualization.
    Holford NH; Buclin T
    Ther Drug Monit; 2012 Oct; 34(5):565-8. PubMed ID: 22960736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma and tissue binding considerations in drug disposition.
    Wilkinson GR
    Drug Metab Rev; 1983; 14(3):427-65. PubMed ID: 6347593
    [No Abstract]   [Full Text] [Related]  

  • 11. Assessing covalent binding of reactive drug metabolites by complete protein digestion and LC-MS analysis.
    Mitrea N; LeBlanc A; St-Onge M; Sleno L
    Bioanalysis; 2010 Jul; 2(7):1211-21. PubMed ID: 21083235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-binding cavities in long-lived biologics: cause for concern but also potential benefit.
    Panayotatos N
    J Clin Pharmacol; 2008 Oct; 48(10):1208-11. PubMed ID: 18812610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Principles of therapeutic drug monitoring].
    Widmer N; Csajka C; Werner D; Grouzmann E; Decosterd LA; Eap CB; Biollaz J; Buclin T
    Rev Med Suisse; 2008 Jul; 4(165):1644-8. PubMed ID: 18767290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Posology and therapeutic follow-up of drugs].
    Soins; 1998 Sep; (628):57-8. PubMed ID: 9823268
    [No Abstract]   [Full Text] [Related]  

  • 15. Drugs targeting protein-protein interactions.
    Chène P
    ChemMedChem; 2006 Apr; 1(4):400-11. PubMed ID: 16892375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An introduction to drug testing: the expanding role of mass spectrometry.
    Hammett-Stabler C; Cotten SW
    Methods Mol Biol; 2012; 902():1-13. PubMed ID: 22767103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The mathematics of drug dose individualization should be built with random-effects linear models.
    Diaz FJ; de Leon J
    Ther Drug Monit; 2013 Apr; 35(2):276-7. PubMed ID: 23503456
    [No Abstract]   [Full Text] [Related]  

  • 18. [Changes in the effect of drugs due to reciprocal interference with their protein binding and catabolism].
    Remmer H
    Dtsch Med Wochenschr; 1974 Mar; 99(9):413-9. PubMed ID: 4857236
    [No Abstract]   [Full Text] [Related]  

  • 19. Covalently bound metabolites as a measure of dose: the pharmacokinetic aspect.
    Gillette JR; Monks TJ; Lau SS
    Dev Toxicol Environ Sci; 1983; 11():265-72. PubMed ID: 6677461
    [No Abstract]   [Full Text] [Related]  

  • 20. Response to Diaz and de Leon "the mathematics of drug dose individualization should be built with random effects linear models".
    Holford NH; Buclin T
    Ther Drug Monit; 2013 Dec; 35(6):873-4. PubMed ID: 24263647
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.